



Press Release
October 16, 2013
Gothenburg

Election Committee of XVIVO Perfusion AB (publ)

The following people have been appointed as members of XVIVO Perfusion's Election Committee for the 2014 Annual General Meeting:

Gösta Johannesson, representing Bure Equity AB, the largest shareholder
Thomas Olausson, the third largest shareholder
Martin Lewin, representing Eccenovio AB, the fourth largest shareholder

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company Election Committee which were determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on May 7, 2013.

The Annual General Meeting of XVIVO Perfusion AB (publ) will be held on April 29, 2014 in Gothenburg. Shareholders who wish to have an item considered at the Annual General Meeting can submit a written request to the Board to this effect. Such a request for an item to be considered is to be sent to XVIVO Perfusion AB (publ), Att: Chairman of the Board, Box 53015, 400 14 Gothenburg, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

October 16, 2013
XVIVO Perfusion AB (publ)

For further information, please contact
Christoffer Rosenblad, CFO, +46 31-788 21 59, christoffer.rosenblad@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 16, 2013 at 2:30 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.